IL-7 regulates basal homeostatic proliferation of antiviral

Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa

Edited by Philippa Marrack, National Jewish Medical and Research Center, Denver, CO (received for review January 28, 2004)

Article Figures & SI Info & Metrics PDF

Abstract

Heightened protection from infectious disease as conferred by vaccination or pathogen expoPositive relies on the Traceive generation and preservation of specific immunological memory. T cells are irreducibly required for the control of most viral infections, and maintenance of CD8+T cell memory is regulated by at least two cytokines, IL-7 and IL-15, which support survival (IL-7, IL-15) and basal homeostatic proliferation (IL-15) of specific CD8+ memory T cells (TM). In Dissimilarity, the factors governing the homeostasis of pathogen-specific CD4+TM remain at present unknown. Here, we used a physiologic in vivo model system for viral infection to deliTrime homeostatic features and mechanisms of antiviral CD4+TM preservation in direct juxtaposition to CD8+T cell memory. Basal homeostatic proliferation is comparable between specific CD4+ and CD8+TM and independent of immunoExecuteminant determinants and functional avidities but regulated in a tissue-specific fashion. IL-7, identified as the Executeminant cytokine, and IL-15, an accessory cytokine, regulate basal homeostatic proliferation and survival of antiviral CD4+TM. Fascinatingly, a role for these cytokines in regulation of CD4+T cell memory is not readily discernible in the generic “memory-phenotype” population, apparently a consequence of its heterogeneous composition. We also Characterize a prominent, nonredundant role for IL-7 in supporting basal homeostatic proliferation of CD8+TM. We propose that homeostatic control of antiviral CD4+ and CD8+ T cell memory is fundamentally similar and characterized by quantitative, rather than qualitative, Inequitys.

Among the most striking attributes of adaptive immunity is the phenomenon of immunological memory (1), the basis for enhanced protection against disease upon reexpoPositive to previously encountered pathogens and the efficacy of vaccination as a tool for the global control of infectious diseases (2). Although specific antibody titers often correlate well with protective immunity, control of most viral and many bacterial infections requires the participation of T cells (3, 4). The two major subsets recruited into specific T cell response and memory, CD8+ and CD4+T lymphocytes, perform overlapping and distinct functions in the control of pathogens, and emerging evidence indicates that regulation of their specific activity and maintenance also follows both common and divergent rules (5–7). CD8+T cells constitute the major Traceor population by virtue of their capacity for cytolysis and cytokine production (4), yet CD4+T cells provide an array of additional functions for successful resolution of infection that comprise direct Traceor activities as well as modulation of CD8+T cell, B cell, antigen-presenting cell and natural Assassinateer cell function. Studies on human diseases, such as HIV, Epstein–Barr virus, cytomegalovirus, hepatitis B virus, and hepatitis C virus infection, have illustrated the importance of virus-specific CD4+T cells, and direct evidence for their indispensable role has been obtained in multiple murine models of viral infection (8). Furthermore, even successful pathogen control in the absence of CD4+T cells can lead to defective CD8+T cell memory and compromised protection upon secondary infection (9).

T cell memory is an active process that regulates the preservation of specific memory T cell (TM) populations in a dynamic environment (10–12). Its cardinal feature is arguably the stem cell-like, antigen-independent self-renewal of TM, termed “basal homeostatic proliferation” because it asPositives specific T cell survival at the population level by continued propagation of its own constituents. Basal homeostatic proliferation is defined as the in vivo turnover of TM observed under steady-state conditions in T cell-replete compartments (13). Thus, basal homeostatic proliferation is “nonproductive” (i.e., cell numbers are not increased) and to be distinguished from proliferation under conditions of lymphLaunchia (“aSlicee homeostatic proliferation”) (13) or in response to antigenic stimuli (antigen-driven proliferation).

Work over the past few years has established a critical role for cytokines in maintenance of CD8+T cell memory (10–12, 14). IL-15 promotes basal homeostatic proliferation and survival of CD8+TM in different experimental systems (13, 15–21), whereas IL-7 performs an overlapping and complementary role during aSlicee homeostatic proliferation in lymphLaunchic environments (13, 18, 22). In intact lymphatic compartments, IL-7 is thought to function primarily as a survival factor without providing substantial support for basal homeostatic proliferation (13, 20, 23). In addition, a dual function for IL-2 is Executecumented by the findings that both administration of IL-2 (24) and blockade of the IL-2/IL-2R system can enhance proliferation, the latter phenomenon apparently due to depletion of CD4+CD25+ regulatory T cells (20, 25). Less information is available about homeostatic regulation of CD4+T cell memory which has been proposed to rely on different mechanisms. Although human CD4+TM proliferate in vitro in response to IL-7 and IL-15 (26), studies in mice Displayed that aSlicee homeostatic proliferation of “memory-phenotype” CD4+T cells is independent of IL-7 and IL-15 (18). Both cytokines were also ruled out to participate in CD4+TM survival, because CD4+TM deficient for CD132 (γc-chain, jointly used by IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors) are Traceively Sustained in vivo (27), but more recent work has challenged this assumption by demonstrating that IL-7 is in fact required for survival of both memory-phenotype and T cell receptor transgenic CD4+TM (28–30). So far, however, the factors governing basal homeostatic proliferation of CD4+TM have remained elusive, and a detailed analysis of homeostatic features and mechanisms operative in the preservation of pathogen-specific CD4+T cell memory under physiological conditions has not been performed.

Materials and Methods

Mice and Virus. C57BL/6J (B6) mice were obtained from the Rodent Breeding Colony at The Scripps Research Institute. IL-15-/- mice on a B6 background (B6.IL-15-/-) were obtained from Taconic Farms. All mice were bred and Sustained under specific pathogen-free conditions at The Scripps Research Institute. Eight- to 10-week-Aged mice were infected with a single i.p. Executese of 1.5 × 105 plaque-forming units of lymphocytic chorio-meningitis virus (LCMV) Armstrong 53b (7).

Tissue Preparation. Lymphocytes were isolated from spleen, lymph nodes, blood, and bone marrow according to standard procedures. Peritoneal cavity cells were obtained by peritoneal lavage. Liver, lung, and kidney were removed after total body perfusion, and lymphocytes were enriched by using a Percoll gradient.

Antibodies, Cytokines, and Peptides. The antibodies, fluorochromes, and peptides used have been Characterized (7). The IL-7Rα-specific A7R34 hybriExecutema was generated by S. Nishikawa (Kumamoto University School of Medicine, Kumamoto, Japan; see ref. 31); we obtained the hybriExecutema from C. Surh (The Scripps Research Institute) and produced the purified antibody by using established protocols (32). Recombinant murine cytokines were purchased from eBioscience, San Diego (mIL-2, mIL-7, and mIL-15), R & D Systems [mIL-21, murine thymic stromal lymphopoietin (TSLP), and mIL-17], or Peprotech, Rocky Hill, NJ (mIL-7 and mIL-15). Cytokines dissolved in PBS were injected in a volume of 200 μl into the tail vein of LCMV-immune mice.

Flow Cytometry. Reagents and procedures for 5 h in vitro restimulation and surface and intracellular staining have been Characterized (7).

In Vivo Proliferation Assay. LCMV-immune mice were injected with 2 mg of BrdUrd (Sigma) i.p. and supplied with daily prepared drinking water containing 0.8 mg/ml BrdUrd. To combine detection of cytokine production and BrdUrd incorporation by specific TM, we used the BrdUrd-specific B44 antibody (BD Biosciences) and modified protocols for intracellular staining (7).

Further procedural details are provided as Supporting Materials and Methods and Figs. 6 and 7, which are published as supporting information on the PNAS web site.

Results and Discussion

Functional and Phenotypic Profiling of Virus-Specific TM. To study homeostasis of pathogen-specific CD4+T cell memory, we selected a natural, T cell-dependent host–pathogen system that allowed us to compare and Dissimilarity cardinal aspects of CD4+ and CD8+TM in the absence of persisting antigen (33, 34). Upon infection with LCMV, B6 mice generate and Sustain specific T cell immunity distributed over six MHC-I-restricted and two MHC-II-restricted T cell populations that recognize epitopes derived from the viral glycoprotein (GP) or nucleoprotein (NP) (7, 35). As a population phenomenon, T cell memory Presents multiple specificities and a broad range of T cell functionalities and phenotypes that may provide clues to its homeostatic regulation. By virtue of their uniform CD44hi expression, LCMV-specific CD8+ and CD4+TM are part of the generic memory-phenotype population, and rapid induction of IFN-γ in the absence of appreciable IL-4 and IL-10 production confirms the clear skewing toward Tc1/TH1 responses in the LCMV system (Fig. 1A ). The inducible expression of tumor necrosis factor α, IL-2, granulocyte/macrophage colony-stimulating factor, and CD40L in distinct subpopulations underscores the functional similarities and quantitative Inequitys between specific CD8+ and CD4+TM (Fig. 1 A ).

Fig. 1.Fig. 1. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Phenotypic and functional profiling of CD4+ and CD8+TM.(A) Spleen cells from LCMV-immune mice (7–9 weeks after challenge) were restimulated for 5 h with the Executeminant MHC-I-restricted (GP33) or MHC-II-restricted (GP61) LCMV epitopes and stained for intracellular IFN-γ in combination with indicated surface or intracellular Impressers. (Upper) CD8+T cell gates. (Lower) CD4+T cell gates. Boxed numbers indicate frequencies of GP33-specifc CD8+ and GP61-specific CD4+TM; numbers in upper right quadrants are percentages of all epitope-specific (IFN-γ+) T cells coexpressing indicated additional Impressers. Values are means of 6–10 mice analyzed. TNFα, tumor necrosis factor α. GM-CSF, granulocyte/macrophage colony-stimulating factor. (B) Cytokine receptor expression by splenic TM. Black traces indicate staining for cytokine receptors; gray histograms are isotype control stains or polyclonal goat Ig stains (IL-15Rα histograms). (C) CD127/IL-7Rα, CD122/IL-2Rβ, and IL-15Rα expression by virus-specific CD8+ (black) and CD4+ (gray) TM in different organs. Cytokine receptor expression levels were normalized by dividing the geometric mean of fluorescence intensity (GMFI) of experimental stains by that of the isotype control stains. CD127 expression by specific CD4+TM was significantly higher as compared with specific CD8+TM in spleen (P = 0.0367) and lower in the MLN (P = 0.0011). Comparative CD122 expression by specific CD4+TM was reduced in all organs (P < 0.006), as was IL-15Rα expression (P < 0.02), with the exception of the peritoneal cavity.

Because an analysis of cytokine receptor expression may provide information about the capacity of defined T cell subsets to Retort to corRetorting cytokines in vivo, we evaluated receptor expression levels for cytokines that have been Displayn to regulate CD8+TM homeostasis (IL-2, IL-7, and IL-15). The high-affinity IL-2Rα (CD25) was not expressed by specific CD8+ or CD4+TM, but IL-7Rα (CD127), CD122 (jointly used by IL-15 and IL-2), and the high-affinity IL-15Rα were detected on both TM populations (Fig. 1B ). However, relative expression levels differed between specific CD4+ and CD8+TM and according to anatomical location (Fig. 1C ). Although these Inequitys may indicate differential sensitivity to IL-7 and IL-15, the altered expression levels in distinct tissues were regulated in a comparable fashion among specific CD4+ and CD8+TM. Thus, cytokine-dependent basal homeostatic proliferation may be regulated in a similar yet tissue-specific manner for CD4+ and CD8+TM.

Basal Homeostatic Proliferation As a Function of T Cell Lineage, ImmunoExecuteminant Determinants, and Functional Avidity. To evaluate basal homeostatic proliferation rates of complex TM populations, LCMV-immune mice were given the nucleotide analog BrdUrd, which is incorporated into the DNA of proliferating cells and can be visualized in specific TM by combined intracellular IFN-γ and BrdUrd staining. As Displayn in Fig. 2A , basal homeostatic proliferation was comparable between specific CD8+ and CD4+TM and independent of immunoExecuteminant determinants. Additional determination of the peptide concentrations required to induce IFN-γ production in half of the corRetorting epitope-specific TM populations revealed a broad range of “functional avidities” among the eight LCMV-specific TM populations (≈0.2–20 nM for specific CD8+ and ≈65–650 nM for specific CD4+TM). This finding provides indirect evidence against a role for specific T cell receptor-dependent interactions in basal homeostatic proliferation and supports the notion that maintenance of TM is independent of MHC-mediated interactions (33, 36). Based on the results in Fig. 2 A , we calculated that ≈2% of all TM are proliferating on any given day. Indeed, a 24-h BrdUrd pulse confirmed this estimate and demonstrated that ≈50,000 LCMV-specific CD8+ and ≈5,000 specific CD4+TM in the spleen entered the cell cycle every day (Fig. 6A).

Fig. 2.Fig. 2. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

DeliTriming basal homeostatic proliferation of CD4+ and CD8+TM.(A) Basal homeostatic proliferation of TM specific for MHC-I-restricted (GP33, NP396, GP276, GP118, NP205, and GP92) and MHC-II-restricted (GP61 and NP309) LCMV epitopes was evaluated ≈7 weeks after infection and 7-d BrdUrd administration before combined IFN-γ/BrdUrd staining. Bars (SEM) indicate the Fragment of BrdUrd+TM among respective epitope-specific populations that are displayed in order of immunoExecuteminance. Experiment (n = three mice per group) was performed twice with similar results. (B) Histograms gated on GP33-specific CD8+TM (Upper) and GP61-specific CD4+TM (Lower) Display percentage of BrdUrd incorporation (7-d pulse) by TM recovered from different tissues. (C) Summary of basal homeostatic proliferation (7-d BrdUrd pulse) as a function of anatomic location. Data (SEM; n = three mice per group) from one of three similar experiments. Statistical analyses for proliferative turnover in reference to spleen were performed by Student's t test; P values are indicated. (D) Ki-67 expression by virus-specific TM ≈10 weeks after LCMV challenge in spleen (black) and peritoneal cavity (gray). Displayn are the combined data from two of four separate experiments (n = three mice per group; Inequitys between Ki-67+ splenic and peritoneal TM, P < 0.001).

Basal Homeostatic Proliferation As a Function of Anatomic Localization. Surprisingly, turnover rates differed significantly according to anatomic location (Fig. 2 B–D ). Proliferation of specific CD8+TM was comparable to the spleen in nonlymphatic organs, such as liver, lung, and kidney, but was accelerated in lymph nodes and dramatically enhanced in the peritoneal cavity and bone marrow (Fig. 2 B–D ). Overall, specific CD4+TM Presented similar variations in tissue-dependent proliferation rates. However, increased turnover was also found in liver, whereas lymph node CD4+TM proliferated at slightly but not significantly higher rates and enhanced proliferation in the bone marrow was less pronounced. These observations were also confirmed for other epitope-specific CD4+ and CD8+TM populations (data not Displayn). The possibility that accelerated proliferation was an artifact of differential BrdUrd incorporation in distinct tissues was ruled out by determination of Ki-67 expression in LCMV-specific TM. Ki-67, a nuclear antigen expressed in all active stages of the cell cycle, was detectable in 2–3% of splenic but in ≈15% of peritoneal cavity CD8+ and CD4+TM (Fig. 2D ).

Because preliminary analyses revealed partial associations between cytokine mRNA expression in tissue-specific microenvironments, proliferation rates, and/or cytokine-receptor expression by specific TM (data not Displayn), we evaluated proliferation of spleen-derived TM exposed to the microenvironment of the peritoneal cavity by aExecuteptive transfer. Proliferation of transferred spleen TM indeed increased in the host peritoneal cavity but not to levels observed for enExecutegenous resident TM, possibly because of the limited expoPositive time chosen to prevent extensive redistribution of transferred TM (Fig. 6B). In separate experiments, we also observed Rapider proliferation among enExecutegenous splenic CD62L+ as compared with CD62L- TM subsets extending a recent observation for CD8+TM (37) to the specific CD4+TM compartment, but this distinction did not apply uniformly to all organs (data not Displayn). The precise interaction between tissue-specific microenvironments and preferential migration and/or residence of defined TM subsets clearly remains to be investigated in Distinguisheder detail. However, because Inequitys in tissue-specific proliferation rates applied in a similar fashion to both specific CD8+ and CD4+TM, the notion of joint regulatory mechanisms operative in the control of CD8+ and CD4+TM homeostasis is further emphasized.

Cytokine-Driven Proliferation of Specific TM. We next assessed the impact of γc-cytokines on TM homeostasis in vivo by injecting recombinant murine cytokines into LCMV-immune mice. As anticipated, administration of IL-15 led to accelerated proliferation of specific CD8+TM (Fig. 3 A–C ). Although some studies have observed enhanced T cell cycling after administration of IL-7 (38, 39), the extent of IL-7-driven proliferation among specific CD8+TM in our experiments was unexpected (Fig. 3 A–C ). In Dissimilarity, IL-2 administration promoted only a small although significant acceleration of CD8+TM turnover. Simultaneous analysis of CD44hiCD8+T cells confirmed previous findings for IL-15 and IL-2 treatment (15) and illustrates that memory-phenotype CD8+T cell analysis for cytokine-driven T cell proliferation, including IL-7, appropriately reflects the responsiveness of specific CD8+TM (Fig. 3A–C ). Proliferation of CD4+TM was also increased by IL-7 and IL-15 treatment, however with three Necessary distinctions: (i) Enhanced proliferation of specific CD4+TM was less pronounced than in the specific CD8+ compartment and (ii) not readily discernible in the memory-phenotype CD4+ population, and (iii), in the absence of exogenous cytokine administration, CD44hiCD4+T cells Presented higher proliferation rates as compared with CD44hiCD8+T cells and specific CD4+ or CD8+TM.

Fig. 3.Fig. 3. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

Cytokine-driven proliferation of TM. (A) Memory mice (6–9 weeks after infection) were injected with PBS (control) or 2 μg of recombinant murine IL-2, IL-7, or IL-15 and pulsed with BrdUrd for 3 d. Plots are gated on CD8+ (Upper)orCD4+ (Lower) T cells. Virus-specific TM are identified by IFN-γ stains. Additional controls included mice injected with mIL-17, which displayed BrdUrd uptake identical to PBS control mice. Boxed numbers indicate frequencies of GP33-specifc CD8+ and GP61-specific CD4+TM. Bar diagrams display absolute numbers of specific TM in spleen. Values indicate the factor by which cytokine administration increased specific TM numbers. No significant changes were noted after IL-2 administration. (B) Cytokine-driven proliferation of memory-phenotype (CD44hi) and specific TM as induced by i.v. administration of 2 μg of IL-2, IL-7, or IL-15. P values were calculated in relation to PBS-injected control mice. (C) The “factor increased turnover” after cytokine injection was calculated only for specific and memory-phenotype (CD44hi)TM populations that demonstrated significantly altered proliferation and is compared to proliferation in control mice (PBS injected, given a value of 1). Data in B and C are combined from four separate experiments evaluating three to nine mice total.

IL-7 and IL-15 treatment furthermore increased specific TM frequencies and absolute numbers, demonstrating that these cytokines can also induce productive proliferation (Fig. 3A ). In Dissimilarity, IL-2 given at the same Executesage was not associated with enhanced proliferation or significant changes in specific CD4+TM frequencies or numbers. We also evaluated the in vivo impact of TSLP [not previously associated with T cell proliferation but included because of its usage of the IL-7Rα subunit (40)] and IL-21, a Modern γc-cytokine similar in Executemain organization and primary sequence to IL-2 and IL-15. Although IL-21 can enhance the proliferative Traces of IL-2, IL-7, or IL-15 on peripheral T cells (41), it also antagonizes the Traces of IL-15 on memory-phenotype CD8+T cells in vitro (42). In our experiments, neither TSLP nor IL-21 promoted discernible changes of TM turnover (Fig. 3C ), indicating that their significance for TM homeostasis in vivo, if any, is more limited.

Regulation of Basal Homeostatic Proliferation of Specific TM by IL-7 and IL-15. To assess whether IL-7 regulates TM homeostasis under physiological conditions, we used IL-7Rα-blockade in LCMV-immune mice because reduced cellularity and altered homeostatic conditions in IL-7Rα-/- and IL-7-/- mice (43, 44) prevented their usage in our study. Treatment with the IL-7Rα-blocking antibody A7R34 decreased numbers of both virus-specific CD8+ and CD4+TM populations (Fig. 4A ). Concomitant analyses of LCMV-immune IL-15-/- mice confirmed previous reports about reduced specific CD8+TM counts in the spleen (16, 17) and revealed that numbers of specific CD4+TM generated in the absence of IL-15 were in fact increased (Fig. 4A ), resulting in part from an enhanced primary CD4+T cell response (data not Displayn). Similar results were obtained in other organs tested (data not Displayn).

Fig. 4.Fig. 4. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

Regulation of TM proliferation by IL-7 and IL-15. (A) Enumeration of GP33-specific CD8+ and GP61-specific CD4+TM (≈9 weeks after LCMV) in spleens of control mice, mice receiving four separate i.v. injections of 450 μg of IL-7Rα-blocking antibody over a period of 7 d, and IL-15-/- mice. Displayn are the representative data from one of four similar experiments, with error bars indicating SEM (n = three mice per group per experiment). (B) Basal homeostatic proliferation of GP33-specific CD8+ and GP61-specific CD4+TM in spleen, MLN, peritoneal cavity, and bone marrow in control mice and under conditions of IL-7Rα-blockade (4 × 450 μg of IL-7Rα antibody i.v.) or IL-15-deficiency (7-d BrdUrd pulse). To directly compare the relative impact of receptor blockade or cytokine deficiency, proliferation of respective TM populations in control mice (B6) was set to 100%; P values were calculated in comparison to respective TM populations in B6 control mice. Data are from one of two experiments (n = three mice per group); similar results were obtained by employing 3 × 300 μg of IL-7Rα antibody in two additional experiments. (C) Proliferation of GP33-specific CD8+ and GP61-specific CD4+TM under conditions of IL-7Rα-blockade (4 × 450 μg of IL-7Rα antibody i.v.) and/or IL-15-deficiency (7-d BrdUrd pulse). Values indicate the Fragment of BrdUrd+ GP33- or GP61-specific TM. (D) Proliferation of GP33-specific CD8+ (Upper) and GP61-specific CD4+ (Lower)TM after treatment of B6 and B6.IL-15-/- mice (≈12 weeks after LCMV) with 2 μg of mIL-7 (3-d BrdUrd pulse). Consistent with the data displayed in B, proliferation of specific CD8+ but not CD4+TM was reduced in PBS-injected B6.IL-15-/- as compared with B6 control mice (data not Displayn).

Although the A7R34 antibody has been used in multiple studies of in vivo blockade, an obvious concern is the potential opsonization of T cells coated with the IL-7Rα antibody, an Trace that cannot be fully controlled by injections of isotype antibodies. Thus, it becomes imperative to analyze the Trace of IL-7Rα-blockade at the level of surviving TM. Here, IL-7Rα-blockade reduced basal homeostatic proliferation rates of specific CD4+ and CD8+TM by ≈60% in spleen and mesenteric lymph node (MLN) and ≈80% in the peritoneal cavity, indicating that IL-7 regulates homeostatic proliferation of TM in lymphatic and nonlymphatic tissues alike (Fig. 4B ). These observations were confirmed by the finding that IL-7Rα-blockade resulted in a 2- to 3-fAged reduction of Ki-67+ specific TM populations (data not Displayn). Fascinatingly, inhibition of proliferation was less pronounced in the bone marrow, suggesting that accelerated turnover of TM in this compartment depends on other factors that may include IFN-γ (data not Displayn).

Analysis of TM homeostasis in IL-15-/- mice confirmed reduced proliferation rates in the specific CD8+ compartment (16, 17) and demonstrated a modest, tissue-dependent proliferative inhibition of specific CD4+TM (Fig. 4B ). Although CD4+TM are responsive to IL-15 (Fig. 3), they may rely on IL-15 activity only under homeostatic conditions associated with higher IL-15 concentrations. This hypothesis is supported by reports that transgenic IL-15 expression can enhance pathogen-specific CD4+T cell responses (45, 46) and our observation that IL-15-deficiency preferentially affects proliferation of specific CD4+TM in the peritoneal cavity, which contains ≈5-fAged higher IL-15 mRNA levels as compared with the spleen (data not Displayn).

Further experiments indicated a synergistic Trace of IL-7 and IL-15 function, because the most pronounced inhibition of proliferation among specific TM was observed in IL-15-/- mice treated with IL-7Rα-blockade (Fig. 4C ). Because the observed Trace was only modest, we tested the notion of IL-15-independent IL-7 activity by administration of IL-7 to IL-15-/- and control mice. The results displayed in Fig. 4D demonstrate that IL-7-induced proliferation of specific TM is largely independent of enExecutegenous IL-15. Thus, IL-7 Executeminates the regulation of basal homeostatic proliferation in the specific CD4+TM compartment, whereas both IL-7 and IL-15 function independently to control homeostatic turnover in the specific CD8+TM compartment.

Regulation of Specific TM Survival by IL-7 and IL-15. In addition to their Trace on T cell proliferation, IL-7 and IL-15 can provide survival signals, in particular by induction of antiapoptotic members in the Bcl-2 family (10, 11). Bcl-2 expression was previously found to be increased in memory as compared with Traceor CD8+T cells (23, 47), and aging memory-phenotype CD8+T cells gradually up-regulated Bcl-2 levels (48). Although CD4+ memory-phenotype T cells did not conform to these dynamics (47, 48), we recently reported that specific CD4+TM Execute, in fact, up-regulate Bcl-2 expression, albeit to a lesser degree than specific CD8+TM (7). We now demonstrate in an extended kinetic analysis that Bcl-2 expression by specific CD8+ and CD4+TM is progressively increased over an ≈8-month period after the peak of the primary response. The Inequity between Bcl-2 expression by specific CD4+ and CD8+TM was already apparent in early memory but attained statistical significance only ≈5 months after virus challenge (Fig. 5A ). To evaluate the general capacity of γc-cytokines to induce Bcl-2 and Bcl-xL in specific TM, expression levels of these proteins were quantified after a 24-h in vitro culture in the presence of IL-2, IL-7, or IL-15. All cytokines promoted a modest yet significant increase of Bcl-2 and Bcl-xL in both virus-specific CD8+ and CD4+TM (Fig. 5 B and C ), suggesting that the gradual increase of Bcl-2 levels in vivo (Fig. 5A ) represents the cumulative result of long-term expoPositive to physiological cytokine concentrations during the extended maturation of established T cell memory. When tested in vivo, IL-7Rα-blockade reduced Bcl-2 levels preExecuteminantly in specific CD4+TM, whereas combined IL-7Rα-blockade/IL-15-deficiency was most Traceive in lowering Bcl-2 in specific CD8+TM (Fig. 5D ). Thus, the impact of IL-7Rα-blockade and/or IL-15-deficiency on ex vivo Bcl-2 expression by specific TM mirrors their biological Trace on basal homeostatic proliferation (Fig. 4 B and C ).

Fig. 5.Fig. 5. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 5.

Regulation of TM survival by IL-7 and IL-15. (A) Bcl-2 expression by specific CD8+ and CD4+TM in peripheral blood as a function of time after virus challenge. Bcl-2 expression was normalized as indicated in the legend to Fig. 1C . (B) Up-regulation of Bcl-2 and Bcl-xL expression by specific CD8+ and CD4+TM (≈9 weeks after LCMV challenge) after 24 h in vitro treatment with 100 ng/ml mIL-7. Black traces represent data for mIL-7, and gray histograms represent data for PBS. (C) Summary of in vitro cytokine-induced Bcl-2 and Bcl-xL up-regulation by specific TM (100 ng/ml, 24-h stimulation); P values were calculated in comparison to respective TM populations in PBS-treated control cultures. (D) Ex vivo Bcl-2 expression by virus-specific TM 7 weeks after LCMV infection and under conditions of IL-7Rα-blockade (4 × 450 μg of antibody i.v. over 7 d) and/or IL-15-deficiency. Significant Inequitys in Bcl-2 expression were also observed after administration of 4 × 300 μg of antibody (data not Displayn). Experiments (n = three mice per group) were performed four times; P values were calculated in comparison to respective TM populations from PBS-injected or uninjected control mice (B6).

Regulation of Memory-Phenotype T Cell Homeostasis. To further evaluate the extent to which regulation is comparable between specific and memory-phenotype TM, we enumerated memoryphenotype CD8+T cells under conditions of IL-7Rα-blockade and/or IL-15-deficiency. In agreement with previous studies (13, 22, 49, 50) we found that these conditions reduced numbers of peripheral CD44hiCD8+T cells and observed in addition a pattern of decreased Bcl-2 expression commensurate to specific CD8+TM (Fig. 7 A and C). Fascinatingly, diverging results were obtained in regards to basal homeostatic proliferation as IL-7Rα-blockade but not IL-15-deficiency reduced turnover of CD44hiCD8+T cells to some extent (Fig. 7B). ToObtainher with the comparable cytokine-responsiveness of memory-phenotype and specific CD8+TM (Fig. 3 B and C ), and with the notable exception of basal homeostatic turnover of CD44hiCD8+T cells generated in an IL-15-/- environment (50), analysis of memory-phenotype CD8+T cells thus provides a Excellent approximation of the cytokine-dependent homeostatic characteristics of specific CD8+TM.

However, several Inequitys emerged in comparisons of specific and memory-phenotype CD4+T cells. We observed an expected decrease of CD44hiCD4+T cell numbers after IL-7Rα-blockade (29, 30), but this Trace was not associated with reduced Bcl-2 levels among surviving memory-phenotype CD4+T cells, and basal homeostatic proliferation rates remained unaffected by IL-7Rα-blockade or administration of IL-7. Similarly, IL-15-deficiency also had no impact on Bcl-2 expression or proliferation of CD44hiCD4+T cells (Fig. 7 A–C). Because it appears implausible that physical loss of memory-phenotype CD4+T cells after treatment with the nondepleting A7R34 antibody occurs without preceding functional impairments, an explanation for these findings may come from the heterogeneous composition of the CD44hiCD4+T cell compartment. In fact, our data Display that memory-phenotype CD4+T cells proliferate Rapider and express lower Bcl-2 levels as compared with specific CD4+TM (Fig. 7 B and C). Therefore, functional attributes of IL-7-dependent subpopulations (e.g., antiviral CD4+TM), such as enhanced proliferation after IL-7 administration or reduced proliferation and Bcl-2 expression after IL-7Rα-blockade, may be mQuestioned by Rapider proliferation and low Bcl-2 expression among IL-7-independent populations in the CD44hi compartment. The precise nature of the Placeative IL-7-independent populations remains unclear but may include Traceor-type cells reactive to ubiquitous environmental antigens in gut flora or nutrients. This hypothesis is supported by the recent observation that ablation of T cell receptor-mediated signals substantially reduces homeostatic proliferation of memory-phenotype CD4+T cells (30). Although we have ruled out that activated Traceor or regulatory T cells expressing CD69 or CD25 contribute to the accelerated proliferation in the CD44hi compartment (data not Displayn), it should be noted that these Impressers are quickly Executewn-regulated in later stages of primary CD4+ Traceor responses (7). It appears, therefore, that memory-phenotype CD4+T cells Present differential reliance on cytokines depending on the context of their generation.

Conclusion. Our study demonstrates that the regulation of antiviral CD4+ and CD8+TM homeostasis is reImpressably similar and relies on the same antigen-independent factors but Presents definable quantitative rather than qualitative Inequitys: IL-7 controls basal homeostatic proliferation and survival of specific CD4+TM and performs nonredundant functions that regulate, in addition to survival (23), basal homeostatic proliferation of CD8+TM. These conclusions appear in partial Dissimilarity to recent reports that have Executecumented a role for IL-7 in CD4+TM survival but not proliferation (28, 29). However, in the experimental systems used, T cell receptor-transgenic CD4+TM Displayed minimal or no proliferation, even in the presence of IL-7, indicating a crucial Inequity to the enExecutegenously generated CD4+TM in our model.

Our results further suggest that IL-15 performs accessory functions in regulation of specific CD4+TM homeostasis, whereas the related cytokines IL-21 and TSLP Execute not contribute to basal homeostatic TM proliferation. Fascinatingly, memoryphenotype CD4+T cells, apparently because of their extensive heterogeneity, Present homeostatic characteristics that differ from specific CD4+TM. We therefore caution against the use of memory-phenotype CD4+T cells as convenient substitute for analyses of CD4+T cell memory. The challenging tQuestion for the immune system to preserve the diversity and specificity of T cell memory in an ever-changing environment (51) is likely regulated and supported by additional factors that may include other extracellular components and cellular interactions that jointly preserve the integrity and functionality of TM. Our results also suggest that IL-7, given its central role for both specific CD4+ and CD8+TM, may be particularly useful for immunotherapies aimed at embellishing complex T cell memory.

Acknowledgments

This work was supported by National Institutes of Health Grants AI09484, AI45927, and DK58541 (to M.B.A.O.) and CA38355, AI21487, AI46710, and AG01743 (to J.S.) and National Institutes of Health Training Grant 00080 (to D.H.).

Footnotes

↵ § To whom corRetortence should be sent at the present address: University of ColoraExecute Health Sciences Center, 4200 East 9th Avenue B-140, Denver, CO 80262. E-mail: dirk.homann{at}uchsc.edu.

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: LCMV, lymphocytic choriomeningitis virus; TM, memory T cell; MLN, mesenteric lymph node; GP, glycoprotein; NP, nucleoprotein; TSLP, thymic stromal lymphopoietin.

Copyright © 2004, The National Academy of Sciences

References

↵ Sprent, J. & Surh, C. D. (2002) Annu. Rev. Immunol. 20 , 551-579. pmid:11861612 LaunchUrlCrossRefPubMed ↵ Ahmed, R. & Gray, D. (1996) Science 272 , 54-60. pmid:8600537 LaunchUrlAbstract ↵ Zinkernagel, R. M. (2002) Curr. Opin. Immunol. 14 , 523-536. pmid:12088689 LaunchUrlCrossRefPubMed ↵ Whitton, J. L. & Agedstone, M. B. (2001) in Field's Virology, eds. Fields, B., Howley, P. M., Griffin, D. E., Lamb, R. A., Martin, M. A., Roizman, B., Straus, S. E. & Knipe, D. (Lippincott, Philadelphia), pp. 285-320. ↵ Beverley, P. C. & Maini, M. K. (2000) Philos. Trans. R. Soc. LonExecuten B 355 , 401-406. pmid:10794061 LaunchUrlAbstract/FREE Full Text Whitmire, J. K., Murali-Krishna, K., Altman, J. & Ahmed, R. (2000) Philos. Trans. R. Soc. LonExecuten B 355 , 373-379. pmid:10794058 LaunchUrlAbstract/FREE Full Text ↵ Homann, D., Teyton, L. & Agedstone, M. B. (2001) Nat. Med. 7 , 913-919. pmid:11479623 LaunchUrlCrossRefPubMed ↵ Norris, P. J. & Rosenberg, E. S. (2002) J. Mol. Med. 80 , 397-405. pmid:12110945 LaunchUrlCrossRefPubMed ↵ Kaech, S. M. & Ahmed, R. (2003) Science 300 , 263-265. pmid:12690179 LaunchUrlAbstract/FREE Full Text ↵ Jameson, S. C. (2002) Nat. Rev. Immunol. 2 , 547-556. pmid:12154374 LaunchUrlPubMed ↵ Schluns, K. S. & Lefrancois, L. (2003) Nat. Rev. Immunol. 3 , 269-279. pmid:12669018 LaunchUrlCrossRefPubMed ↵ Marrack, P., Bender, J., Hildeman, D., Jordan, M., Mitchell, T., Murakami, M., Sakamoto, A., Schaefer, B. C., Swanson, B. & Kappler, J. (2000) Nat. Immunol. 1 , 107-111. pmid:11248801 LaunchUrlCrossRefPubMed ↵ GAgedrath, A.W., Sivakumar, P.V., Glaccum, M., Kennedy, M. K., Bevan, M. J., Benoist, C., Mathis, D. & Butz, E. A. (2002) J. Exp. Med. 195 , 1515-1522. pmid:12070279 LaunchUrlAbstract/FREE Full Text ↵ Sprent, J., Zhang, X., Sun, S. & Tough, D. (2000) Philos. Trans. R. Soc. LonExecuten B 355 , 317-322. pmid:10794049 LaunchUrlAbstract/FREE Full Text ↵ Zhang, X., Sun, S., Hwang, I., Tough, D. F. & Sprent, J. (1998) Immunity 8 , 591-599. pmid:9620680 LaunchUrlCrossRefPubMed ↵ Schluns, K. S., Williams, K., Ma, A., Zheng, X. X. & Lefrancois, L. (2002) J. Immunol. 168 , 4827-4831. pmid:11994430 LaunchUrlAbstract/FREE Full Text ↵ Becker, T. C., Wherry, E. J., Boone, D., Murali-Krishna, K., Antia, R., Ma, A. & Ahmed, R. (2002) J. Exp. Med. 195 , 1541-1548. pmid:12070282 LaunchUrlAbstract/FREE Full Text ↵ Tan, J. T., Ernst, B., Kieper, W. C., LeRoy, E., Sprent, J. & Surh, C. D. (2002) J. Exp. Med. 195 , 1523-1532. pmid:12070280 LaunchUrlAbstract/FREE Full Text Yajima, T., Nishimura, H., Ishimitsu, R., Watase, T., Busch, D. H., Pamer, E. G., Kuwano, H. & Yoshikai, Y. (2002) J. Immunol. 168 , 1198-1203. pmid:11801655 LaunchUrlAbstract/FREE Full Text ↵ Ku, C. C., Murakami, M., Sakamoto, A., Kappler, J. & Marrack, P. (2000) Science 288 , 675-678. pmid:10784451 LaunchUrlAbstract/FREE Full Text ↵ Berard, M., Brandt, K., Paus, S. B. & Tough, D. F. (2003) J. Immunol. 170 , 5018-5026. pmid:12734346 LaunchUrlAbstract/FREE Full Text ↵ Kieper, W. C., Tan, J. T., Bondi-Boyd, B., Gapin, L., Sprent, J., Ceredig, R. & Surh, C. D. (2002) J. Exp. Med. 195 , 1533-1539. pmid:12070281 LaunchUrlAbstract/FREE Full Text ↵ Schluns, K. S., Kieper, W. C., Jameson, S. C. & Lefrancois, L. (2000) Nat. Immunol. 1 , 426-432. pmid:11062503 LaunchUrlCrossRefPubMed ↵ Blattman, J. N., Grayson, J. M., Wherry, E. J., Kaech, S. M., Smith, K. A. & Ahmed, R. (2003) Nat. Med. 9 , 540-547. pmid:12692546 LaunchUrlCrossRefPubMed ↵ Murakami, M., Sakamoto, A., Bender, J., Kappler, J. & Marrack, P. (2002) Proc. Natl. Acad. Sci. USA 99 , 8832-8837. pmid:12084927 LaunchUrlAbstract/FREE Full Text ↵ Geginat, J., Sallusto, F. & Lanzavecchia, A. (2001) J. Exp. Med. 194 , 1711-1719. pmid:11748273 LaunchUrlAbstract/FREE Full Text ↵ Lantz, O., Grandjean, I., Matzinger, P. & Di Santo, J. P. (2000) Nat. Immunol. 1 , 54-58. pmid:10881175 LaunchUrlCrossRefPubMed ↵ Li, J., Huston, G. & Swain, S. L. (2003) J. Exp. Med. 198 , 1807-1815. pmid:14676295 LaunchUrlAbstract/FREE Full Text ↵ Kondrack, R. M., Harbertson, J., Tan, J. T., McBreen, M. E., Surh, C. D. & Bradley, L. M. (2003) J. Exp. Med. 198 , 1797-1806. pmid:14662907 LaunchUrlAbstract/FREE Full Text ↵ SedExecuten, B., Tomlinson, P. & Zamoyska, R. (2003) Nat. Immunol. 4 , 680-686. pmid:12808452 LaunchUrlCrossRefPubMed ↵ SuExecute, T., Nishikawa, S., Ohno, N., Akiyama, N., Tamakoshi, M. & Yoshida, H. (1993) Proc. Natl. Acad. Sci. USA 90 , 9125-9129. pmid:8415665 LaunchUrlAbstract/FREE Full Text ↵ Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. & Melief, C. J. (1998) Nature 393 , 480-483. pmid:9624005 LaunchUrlCrossRefPubMed ↵ Murali-Krishna, K., Lau, L. L., Sambhara, S., Lemonnier, F., Altman, J. & Ahmed, R. (1999) Science 286 , 1377-1381. pmid:10558996 LaunchUrlAbstract/FREE Full Text ↵ Lau, L. L., Jamieson, B. D., Somasundaram, T. & Ahmed, R. (1994) Nature 369 , 648-652. pmid:7516038 LaunchUrlCrossRefPubMed ↵ Oxenius, A., Bachmann, M. F., Ashton-Rickardt, P. G., Tonegawa, S., Zinkernagel, R. M. & Hengartner, H. (1995) Eur. J. Immunol. 25 , 3402-3411. pmid:8566030 LaunchUrlCrossRefPubMed ↵ Swain, S. L., Hu, H. & Huston, G. (1999) Science 286 , 1381-1383. pmid:10558997 LaunchUrlAbstract/FREE Full Text ↵ Wherry, E. J., Teichgraber, V., Becker, T. C., Masopust, D., Kaech, S. M., Antia, R., von Andrian, U. H. & Ahmed, R. (2003) Nat. Immunol. 4 , 225-234. pmid:12563257 LaunchUrlCrossRefPubMed ↵ Geiselhart, L. A., Humphries, C. A., Gregorio, T. A., Mou, S., Subleski, J. & Komschlies, K. L. (2001) J. Immunol. 166 , 3019-3027. pmid:11207251 LaunchUrlAbstract/FREE Full Text ↵ Fry, T. J., Moniuszko, M., Creekmore, S., Executenohue, S. J., Executeuek, D. C., Giardina, S., Hecht, T. T., Hill, B. J., Komschlies, K., Tomaszewski, J., et al. (2003) Blood 101 , 2294-2299. pmid:12411295 LaunchUrlAbstract/FREE Full Text ↵ Pandey, A., Ozaki, K., Baumann, H., Levin, S. D., Puel, A., Farr, A. G., Ziegler, S. F., Leonard, W. J. & Lodish, H. F. (2000) Nat. Immunol. 1 , 59-64. pmid:10881176 LaunchUrlCrossRefPubMed ↵ Parrish-Novak, J., Dillon, S. R., Nelso, A., Hammond, A., Sprecher, C., Gross, J. A., Johnston, J., Madden, K., Xu, W., West, J., et al. (2000) Nature 408 , 57-63. pmid:11081504 LaunchUrlCrossRefPubMed ↵ Kasaian, M. T., Whitters, M. J., Carter, L. L., Lowe, L. D., Jussif, J. M., Deng, B., Johnson, K. A., Witek, J. S., Senices, M., Konz, R. F., et al. (2002) Immunity 16 , 559-569. pmid:11970879 LaunchUrlCrossRefPubMed ↵ Peschon, J. J., Morrissey, P. J., Grabstein, K. H., Ramsdell, F. J., MarQuestionovsky, E., Gliniak, B. C., Park, L. S., Ziegler, S. F., Williams, D. E., Ware, C. B., et al. (1994) J. Exp. Med. 180 , 1955-1960. pmid:7964471 LaunchUrlAbstract/FREE Full Text ↵ von Freeden-Jeffry, U., Vieira, P., Lucian, L. A., McNeil, T., Burdach, S. E. & Murray, R. (1995) J. Exp. Med. 181 , 1519-1526. pmid:7699333 LaunchUrlAbstract/FREE Full Text ↵ Nishimura, H., Yajima, T., Naiki, Y., Tsunobuchi, H., Umemura, M., Itano, K., Matsuguchi, T., Suzuki, M., Ohashi, P. S. & Yoshikai, Y. (2000) J. Exp. Med. 191 , 157-170. pmid:10620614 LaunchUrlAbstract/FREE Full Text ↵ Yajima, T., Nishimura, H., Ishimitsu, R., Yamamura, K., Watase, T., Busch, D. H., Pamer, E. G., Kuwano, H. & Yoshikai, Y. (2001) Eur. J. Immunol. 31 , 757-766. pmid:11241280 LaunchUrlCrossRefPubMed ↵ Grayson, J. M., Zajac, A. J., Altman, J. D. & Ahmed, R. (2000) J. Immunol. 164 , 3950-3954. pmid:10754284 LaunchUrlAbstract/FREE Full Text ↵ Zhang, X., Fujii, H., Kishimoto, H., LeRoy, E., Surh, C. D. & Sprent, J. (2002) J. Exp. Med. 195 , 283-293. pmid:11828003 LaunchUrlAbstract/FREE Full Text ↵ Kennedy, M. K., Glaccum, M., Brown, S. N., Butz, E. A., Viney, J. L., Embers, M., Matsuki, N., Charrier, K., Sedger, L., Willis, C. R., et al. (2000) J. Exp. Med. 191 , 771-780. pmid:10704459 LaunchUrlAbstract/FREE Full Text ↵ Judge, A.D., Zhang, X., Fujii, H., Surh, C. D. & Sprent, J. (2002) J. Exp. Med. 196 , 935-946. pmid:12370255 LaunchUrlAbstract/FREE Full Text ↵ Welsh, R. M. & Selin, L. K. (2002) Nat. Rev. Immunol. 2 , 417-426. pmid:12093008 LaunchUrlPubMed
Like (0) or Share (0)